ADC Therapeutics (ADCT) Stock Price, News & Analysis

Company Overview

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of antibody-drug conjugates (ADCs) to treat hematological malignancies and solid tumors. Utilizing its proprietary pyrrolobenzodiazepine (PBD) cytotoxin platform, the company designs targeted therapies that deliver powerful anti-cancer agents directly to tumor cells while minimizing systemic exposure. ADC Therapeutics oversees all stages of drug development from discovery and preclinical evaluation through clinical trials and regulatory approval.

The company’s lead product, loncastuximab tesirine (marketed as Zynlonta), received regulatory approval for the treatment of relapsed or refractory large B-cell lymphoma. Beyond this first-in-class ADC, ADC Therapeutics has multiple additional candidates in its pipeline, including camidanlumab tesirine for Hodgkin lymphoma and several earlier-stage programs targeting solid tumors and other blood cancers. The organization collaborates with academic institutions and industry partners to explore combination therapies, expand indications, and enhance the therapeutic potential of its ADC platform.

Founded in 2011 as a spin-out of the UK-based ADC specialist Spirogen, ADC Therapeutics is headquartered in Lausanne, Switzerland, with a major research and development hub in Princeton, New Jersey. The company completed its initial public offering on the New York Stock Exchange in 2018 under the ticker ADCT. Led by an experienced management team with deep expertise in oncology drug development and commercialization, ADC Therapeutics continues to execute its strategic vision of bringing targeted, high-potency cancer therapies to patients worldwide.

Key Stats

• Today's Range: $3.03 to $3.18
• 50-Day Range: $1.32 to $3.68
• 52-Week Range: $1.05 to $3.98
• Volume: 503,903 shs
• Average Volume: 600,136 shs
• Market Capitalization: $302.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.75
• Consensus Rating: Buy

ADC Therapeutics Stock Analysis - MarketRank™

ADC Therapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 786th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ADC Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ADC Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ADC Therapeutics are expected to grow in the coming year, from ($1.69) to ($1.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ADC Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ADC Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.23% of the float of ADC Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

ADC Therapeutics has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in ADC Therapeutics has recently increased by 8.39%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ADC Therapeutics does not currently pay a dividend.

Dividend Growth

ADC Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.23% of the float of ADC Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

ADC Therapeutics has a short interest ratio ("days to cover") of 7.2.

Change versus previous month

Short interest in ADC Therapeutics has recently increased by 8.39%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Sentiment

ADC Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ADC Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for ADCT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ADC Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.40% of the stock of ADC Therapeutics is held by insiders.

Percentage Held by Institutions

41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ADCT Stock Analysis - Frequently Asked Questions

How have ADCT shares performed this year?

ADC Therapeutics' stock was trading at $1.99 at the beginning of 2025. Since then, ADCT shares have increased by 53.3% and is now trading at $3.05.

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.38) by $0.02. The business earned $23.03 million during the quarter, compared to analyst estimates of $17.71 million.
Read the conference call transcript.

When did ADC Therapeutics IPO?

ADC Therapeutics (ADCT) raised $126 million in an IPO on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO.

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' top institutional shareholders include Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Redmile Group, Llc, Ameet Mallik and Robert Azelby.
View institutional ownership trends.

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ADC Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:ADCT
• CIK: 1771910
• Web: www.adctherapeutics.com
• Phone: 41-21-653-0200
• Fax: N/A
• Employees: 310
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ADC Therapeutics: $7.75
• High Price Target: $10.00
• Low Price Target: $5.00
• Potential Upside/Downside: +154.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$157.85 million
• Net Margins: -197.64%
• Pretax Margin: -196.28%
• Return on Equity: N/A
• Return on Assets: -45.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.46
• Quick Ratio: 4.16

Sales & Book Value

• Annual Sales: $70.84 million
• Price / Sales: 4.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.10) per share
• Price / Book: -1.45

Miscellaneous

• Outstanding Shares: 99,180,000
• Free Float: 93,822,000
• Market Cap: $302.50 million
• Optionable: Optionable
• Beta: 1.89